Interleukin 6 (IL-6) and other pro-inflammatory cytokines (IL-6 and cytokines)

Interleukin 6 (IL-6) and other pro-inflammatory cytokines, including Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-1 (IL-1), are a diverse group of signaling proteins that play a fundamental role in the orchestration of the immune response and inflammation (UniProt: P05231, P01375). These molecules are secreted by a variety of cells, such as macrophages and T-cells, to facilitate communication during infection or tissue injury. While essential for host defense, the chronic or excessive production of these cytokines is a primary driver of many autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, and life-threatening conditions like cytokine release syndrome (StatPearls: Cytokine Release Syndrome). Therapeutic intervention often targets these molecules using monoclonal antibodies or decoy receptors to neutralize their activity or block their respective receptors (FDA: Actemra Label). By inhibiting these pathways, clinicians can significantly reduce systemic inflammation and prevent tissue damage. However, because these cytokines are vital for normal immune surveillance, their therapeutic blockade is associated with a heightened risk of serious infections and other immune-related complications (PubMed: PMC7151630). Monitoring biomarkers like C-reactive protein is common to assess the efficacy of these interventions.

Other names

Pro-inflammatory cytokinesInflammatory mediatorsInterleukin 6Tumor necrosis factor-alphaInterleukin 1 betaInterleukin 17AInterleukin 12Interleukin 23Cytokine storm mediators

Drugs targeting these cytokines generally act as antagonists by either directly binding to the soluble or membrane-bound cytokine (neutralization) or by binding to the cytokine's specific receptor to prevent ligand-induced signaling (competitive inhibition). For example, IL-6 inhibitors block the formation of the IL-6/IL-6R/gp130 hexameric complex, thereby preventing the activation of the JAK/STAT signaling pathway (StatPearls: Cytokine Release Syndrome; FDA: Actemra Label). TNF inhibitors prevent TNF-alpha from binding to TNFR1 and TNFR2, which inhibits the activation of the NF-kappaB and MAPK pathways involved in cell survival and inflammation (PubMed: PMC2637294).